Lipocationic Polymers for siRNA Delivery via Ring-Opening Polymerization

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for delivering siRNA-based therapies face challenges due to the difficulty in effectively delivering highly anionic biomacromolecular drugs into cells, particularly in achieving controlled chemical and physical properties for precise drug delivery, and the lack of functional groups for siRNA binding and release in existing polymers.

Innovation Solution

Development of a polymer composition through ring-opening polymerization that incorporates tertiary amine and alkyl functional groups, allowing for the direct synthesis of degradable polymers with precise control over molecular weight and composition, enabling efficient siRNA delivery by forming nanoparticles with nucleic acids.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If functionalized lactones are synthesized via low-yielding multi-step pathways with protecting groups, then functional groups for siRNA binding can be introduced, but manufacturing efficiency and scalability are limited

Engineering Contradiction:
Improvesynthesis efficiencyVSAvoidfunctional group incorporation
Core Design Contradiction:
Ease of manufactureVSManufacturing precision

Solution Approach 1:

The synthesis pathway is segmented into two independent parts: (1) preparation of functionalized lactone monomers in one step from commercially available starting materials, and (2) polymerization of these monomers. This segmentation allows optimization of each step separately, achieving high yield in monomer synthesis and scalable polymerization without needing protecting groups.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Functional groups are introduced into the lactone monomers before polymerization occurs. By preparing fully functionalized monomers in advance through one-step reactions from commercial materials, the patent eliminates the need for post-polymerization modification and protecting group chemistry, thereby improving manufacturing efficiency while maintaining functional group integrity.

Inventive Principle:
Principle #10Preliminary action

2Reliability

If degradable polymers with tertiary amine functional groups are synthesized, then siRNA delivery capability is improved, but direct polymerization of tertiary amine functionalized cyclic esters has remained elusive

Engineering Contradiction:
ImprovesiRNA delivery capabilityVSAvoidpolymerization feasibility
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent changes the chemical parameters of the monomer structure by using tertiary amine functionalized cyclic esters with specific molecular weights and functional group arrangements. By optimizing these parameters, the patent achieves successful ring-opening polymerization while maintaining the desired tertiary amine functional groups for siRNA binding, resolving the contradiction between delivery capability and synthesis feasibility.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates composite polymer structures combining degradable polyester backbone with tertiary amine functional groups. This composite approach integrates the benefits of both components: the degradable polyester provides biocompatibility and elimination, while the tertiary amine groups provide siRNA binding capability, achieving both reliability and manufacturability.

Inventive Principle:
Principle #40Composite materials

3Reliability

If polymer functionality is modulated to achieve effective delivery, then delivery efficiency improves, but control over molecular weight and molecular weight distribution becomes challenging

Engineering Contradiction:
Improvedelivery efficiencyVSAvoidmolecular weight control
Core Design Contradiction:
ReliabilityVSManufacturing precision

Solution Approach 1:

The patent employs feedback control in the ring-opening polymerization process by monitoring and adjusting reaction conditions (temperature, catalyst concentration, monomer-to-initiator ratio) to maintain desired molecular weight and distribution. This feedback mechanism allows real-time optimization of polymer properties while ensuring consistent delivery efficiency.

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The patent systematically varies key polymerization parameters including monomer-to-initiator ratio, catalyst concentration, and reaction temperature to precisely control molecular weight and distribution. By establishing clear parameter relationships, the patent achieves both effective delivery efficiency and manufacturing precision over polymer properties.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The polymer composition achieves high delivery efficiency of siRNA, with formulated nanoparticles exhibiting potent gene knockdown in vitro and in vivo, demonstrating improved biocompatibility and efficacy in treating diseases associated with gene overexpression.

Implementation Method 1

polymers are an important class of materials for drug and nucleic acid delivery due to the versatility in constructing different nanostructures including micelles, polyplexes, dendrimers, and polymer-siRNA conjugates

Methodology Applied
Scientific EffectElectrostatic interaction: Electrostatics

Data Source

PatentEP4088741A1Lipocationic polymers and uses thereof
Publication Date: 2022.11.16 BOARD OF RGT THE UNIV OF TEXAS SYST
  • EP4088741A1 patent drawingFigure 1A
  • EP4088741A1 patent drawingFigure 1B
  • EP4088741A1 patent drawingFigure 2

AI summary

Polymers produced by ring opening polymerization which comprises an amino group that can be used in compositions to deliver a nucleic acid such as a miRNA or a siRNA. In some embodiments, compositions which comprise the polymers described herein and a nucleic acid are also provided herein. In some embodiments, these compositions are used to silence one or more genes in vivo or treat a disease or disorder.